Environmental risk factors and multiple sclerosis: An umbrella review of systematic reviews and meta-analyses

The Lancet Neurology

Volumn 14, Issue 3, 2015, Pages 263-273

  Belbasis, Lazaros ^a   Bellou, Vanesa ^a   Evangelou, Evangelos ^a,b   Ioannidis, John P A ^c,d   Tzoulaki, Ioanna ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN G; PROLACTIN; URIC ACID; VIRUS CAPSID ANTIGEN; VIRUS DNA; VITAMIN D;

ACCIDENT; ARTICLE; BCG VACCINATION; BONE DENSITY; CHRONIC CEREBROSPINAL VENOUS INSUFFICIENCY; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DIPHTHERIA; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS INFECTION; FEMUR NECK; FOLIC ACID BLOOD LEVEL; HEPATITIS B; HUMAN; META ANALYSIS (TOPIC); MONONUCLEOSIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RISK FACTOR; SMOKING; SOCIAL STATUS; SYSTEMATIC REVIEW (TOPIC); TETANUS; TONSILLECTOMY; VITAMIN BLOOD LEVEL; ADVERSE EFFECTS; LITERATURE; OBSERVATIONAL STUDY;

ENVIRONMENTAL EXPOSURE; HUMANS; META-ANALYSIS AS TOPIC; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY AS TOPIC; REVIEW LITERATURE AS TOPIC; RISK FACTORS;

EID: 84923285215     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70267-4     Document Type: Article

References (79)

1. Gilden DH Infectious causes of multiple sclerosis. Lancet Neurol 2005, 4:195-202.
2. Atlas of MS 2013: mapping multiple sclerosis around the world 2013, Multiple Sclerosis International Federation, Multiple Sclerosis International Federation, London.
3. Kingwell E, Marriott JJ, Jette N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013, 13:128.
4. Evans C, Beland SG, Kulaga S, et al. Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology 2013, 40:195-210.
5. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One 2010, 5:e12496.
6. Handel AE, Williamson AJ, Disanto G, Dobson R, Giovannoni G, Ramagopalan SV Smoking and multiple sclerosis: an updated meta-analysis. PLoS One 2011, 6:e16149.
7. Simpson S, Blizzard L, Otahal P, Van der Mei I, Taylor B Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011, 82:1132-1141.
8. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010, 9:727-739.
9. Ioannidis JP Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009, 181:488-493.
10. DerSimonian R, Laird N Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
11. Lau J, Ioannidis JP, Schmid CH Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127:820-826.
12. Higgins JP, Thompson SG, Spiegelhalter DJ A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A 2009, 172:137-159.
13. Higgins JP Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 2008, 37:1158-1160.
14. Chinn S A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000, 19:3127-3131.
15. Cochran W The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
16. Higgins JP, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
17. Ioannidis JP, Patsopoulos NA, Evangelou E Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007, 335:914-916.
18. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011, 343:d4002.
19. Egger M, Davey Smith G, Schneider M, Minder C Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
20. Ioannidis JP, Trikalinos TA An exploratory test for an excess of significant findings. Clin Trials 2007, 4:245-253.
21. Ioannidis JP Clarifications on the application and interpretation of the test for excess significance and its extensions. J Math Psychol 2013, 57:184-187.
22. Lubin JH, Gail MH On power and sample size for studying features of the relative odds of disease. Am J Epidemiol 1990, 131:552-566.
23. Bagos PG, Nikolopoulos G, Ioannidis A Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta-analysis. Mult Scler 2006, 12:397-411.
24. Sundqvist E, Bergstrom T, Daialhosein H, et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult Scler 2014, 20:165-173.
25. Liu B, Shen Y, Xiao K, Tang Y, Cen L, Wei J Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res 2012, 34:163-171.
26. Ioannidis JP, Tarone R, McLaughlin JK The false-positive to false-negative ratio in epidemiologic studies. Epidemiology 2011, 22:450-456.
27. Johnson VE Revised standards for statistical evidence. Proc Natl Acad Sci USA 2013, 110:19313-19317.
28. Laupacis A, Lillie E, Dueck A, et al. Association between chronic cerebrospinal venous insufficiency and multiple sclerosis: a meta-analysis. CMAJ 2011, 183:E1203-E1212.
29. Zwischenberger BA, Beasley MM, Davenport DL, Xenos ES Meta-analysis of the correlation between chronic cerebrospinal venous insufficiency and multiple sclerosis. Vasc Endovasc Surg 2013, 47:620-624.
30. Ascherio A, Munch M Epstein-Barr virus and multiple sclerosis. Epidemiology 2000, 11:220-224.
31. Pakpoor J, Disanto G, Gerber JE, et al. The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler 2013, 19:162-166.
32. Demicheli V, Rivetti A, Di Pietrantonj C, Clements CJ, Jefferson T Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review. J Viral Hepat 2003, 10:343-344.
33. Martinez-Sernandez V, Figueiras A Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production. J Neurol 2013, 260:1951-1959.
34. Rutschmann OT, McCrory DC, Matchar DB Immunization and MS: a summary of published evidence and recommendations. Neurology 2002, 59:18343-18370. Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines.
35. Thacker EL, Mirzaei F, Ascherio A Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006, 59:499-503.
36. Hernan MA, Alonso A, Hernandez-Diaz S Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 2006, 67:212-215.
37. Landtblom AM, Flodin U, Soderfeldt B, Wolfson C, Axelson O Organic solvents and multiple sclerosis: a synthesis of the current evidence. Epidemiology 1996, 7:429-433.
38. Hawkes CH Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult Scler 2007, 13:610-615.
39. Zhu Y, Liu HN, Zhang CD, Liang HY [Meta-analysis on relationship between hyperhomocysteinemia and multiple sclerosis]. Zhonghua Yi Xue Za Zhi 2009, 89:3055-3057.
40. Lunny CA, Fraser SN, Knopp-Sihota JA Physical trauma and risk of multiple sclerosis: a systematic review and meta-analysis of observational studies. J Neurol Sci 2014, 336:13-23.
41. Warren SA, Olivo SA, Contreras JF, et al. Traumatic injury and multiple sclerosis: a systematic review and meta-analysis. Can J Neurol Sci 2013, 40:168-176.
42. Artemiadis AK, Anagnostouli MC, Alexopoulos EC Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology 2011, 36:109-120.
43. Goulden R, Ibrahim T, Wolfson C Is high socioeconomic status a risk factor for multiple sclerosis? A systematic review. Eur J Neurol 2014, published online Nov 5.DOI: 10.1111/ene.12586.
44. Zhornitsky S, Yong VW, Weiss S, Metz LM Prolactin in multiple sclerosis. Mult Scler 2013, 19:15-23.
45. Duan S, Lv Z, Fan X, et al. Vitamin D status and the risk of multiple sclerosis: a systematic review and meta-analysis. Neurosci Lett 2014, 570:108-113.
46. Zhu Y, He ZY, Liu HN Meta-analysis of the relationship between homocysteine, vitamin B12, folate, and multiple sclerosis. J Clin Neurosci 2011, 18:933-938.
47. Huang Z, Qi Y, Du S, Chen G, Yan W Bone mineral density levels in adults with multiple sclerosis: a meta-analysis. Int J Neurosci 2014, published online Dec 18. 10.3109/00207454.2014.988332.
48. Aminzadeh KK, Etminan M Dental amalgam and multiple sclerosis: a systematic review and meta-analysis. J Public Health Dent 2007, 67:64-66.
49. Barragan-Martinez C, Speck-Hernandez CA, Montoya-Ortiz G, Mantilla RD, Anaya JM, Rojas-Villarraga A Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis. PLoS One 2012, 7:e51506.
50. Almohmeed YH, Avenell A, Aucott L, Vickers MA Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. PLoS One 2013, 8:e61110.
51. Farez MF, Correale J Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011, 258:1197-1206.
52. Santiago O, Gutierrez J, Sorlozano A, de Dios Luna J, Villegas E, Fernandez O Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production. Eur J Clin Microbiol Infect Dis 2010, 29:857-866.
53. Lunny C, Knopp-Sihota JA, Fraser SN Surgery and risk for multiple sclerosis: a systematic review and meta-analysis of case-control studies. BMC Neurol 2013, 13:41.
54. Monteiro L, Souza-Machado A, Menezes C, Melo A Association between allergies and multiple sclerosis: a systematic review and meta-analysis. Acta Neurol Scand 2011, 123:1-7.
55. Tsivgoulis G, Sergentanis TN, Chan A, et al. Chronic cerebrospinal venous insufficiency and multiple sclerosis: a comprehensive meta-analysis of case-control studies. Ther Adv Neurol Disord 2014, 7:114-136.
56. Tsilidis KK, Panagiotou OA, Sena ES, et al. Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol 2013, 11:e1001609.
57. Tsilidis KK, Papatheodorou SI, Evangelou E, Ioannidis JP Evaluation of excess statistical significance in meta-analyses of 98 biomarker associations with cancer risk. J Natl Cancer Inst 2012, 104:1867-1878.
58. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med 2013, 173:664-671.
59. Compston A, Coles A Multiple sclerosis. Lancet 2008, 372:1502-1517.
60. Cohen JI, Fauci AS, Varmus H, Nabel GJ Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 2011, 3:107fs7.
61. Ascherio A, Munger KL, Lunemann JD The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012, 8:602-612.
62. Lunemann JD, Tintore M, Messmer B, et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 2010, 67:159-169.
63. He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2013, 12. CD009130.
64. van der Mei IA, Simpson S, Stankovich J, Taylor BV Individual and joint action of environmental factors and risk of MS. Neurol Clin 2011, 29:233-255.
65. Monteyne P, Andre FE Is there a causal link between hepatitis B vaccination and multiple sclerosis?. Vaccine 2000, 18:1994-2001.
66. Hernan MA, Jick SS, Olek MJ, Jick H Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004, 63:838-842.
67. Touze E, Fourrier A, Rue-Fenouche C, et al. Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology 2002, 21:180-186.
68. Mikaeloff Y, Caridade G, Rossier M, Suissa S, Tardieu M Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med 2007, 161:1176-1182.
69. Sadovnick AD, Scheifele DW School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 2000, 355:549-550.
70. Zamboni P The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med 2006, 99:589-593.
71. Zamboni P, Galeotti R, Menegatti E, et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80:392-399.
72. Zamboni P, Galeotti R, Menegatti E, et al. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg 2009, 50:1348-1358. e1-3.
73. Zamboni P, Bertolotto A, Boldrini P, et al. Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial. Trials 2012, 13:183.
74. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014, 348:g2035.
75. Tzoulaki I, Siontis KC, Ioannidis JP Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ 2011, 343:d6829.
76. Gallo V, Egger M, McCormack V, et al. STrengthening the Reporting of OBservational studies in Epidemiology-Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement. PLoS Med 2011, 8:e1001117.
77. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007, 4:e296.
78. Dal-Re R, Ioannidis JP, Bracken MB, et al. Making prospective registration of observational research a reality. Sci Transl Med 2014, 6:224cm1.
79. Ioannidis JP The importance of potential studies that have not existed and registration of observational data sets. JAMA 2012, 308:575-576.